- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06745284
En studie for å teste om Survodutide forbedrer hvordan kroppen bruker energi og bryter ned fett hos personer med fedme
En aktiv-komparator-kontrollert, åpen, parallell gruppestudie for å evaluere effekten av Survodutide på energiforbruk og fettsyreoksidasjon hos personer med fedme
This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy and breaks down fat. This study compares survodutide with another medicine called semaglutide. Survodutide is being developed to treat people with obesity.
Semaglutide is already used to treat people with obesity.
Participants are put into 2 groups by chance. One group gets survodutide and the other group gets semaglutide. Participants get survodutide or semaglutide as an injection under the skin once a week. Participants are in the study for 8-10 months depending on how long the treatment is given. During this time, they visit the study site weekly. Some of the visits may also be done at the participant's home instead of the study site.
At some of the visits, doctors test how much energy a participant's body uses. This is done in a special room where they measure the oxygen that is breathed in and the carbon dioxide that is breathed out by the participant. The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Orlando, Florida, Forente stater, 32804
- AdventHealth - Translation Research Institute
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70808
- Pennington Biomedical Research Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion criteria
-
Age of 18 to 65 years (inclusive)
-
Male or female subjects with obesity (defined as a body mass index (BMI) of ≥30 and ≤45 kg/m²)
-
Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information
-
Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
-
In the investigator's opinion, are well-motivated, capable, and willing to:
- Learn how to self-inject the investigational medicinal product (IMP), as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP)
- Inject the IMP or accept injection from a designated person --- Follow trial procedures for the duration of the trial, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise, maintain a diary, complete required questionnaires, and handle the IMP as described in the instruction for use (IFU))
Exclusion criteria:
- Current or history of significant alcohol consumption (defined as intake of >210 g/week in men and >140 g/week in women on average over a consecutive period of more than 3 months) or are unwilling to stop alcohol consumption 48 h before admission to the research facility and until discharge
- History of chronic liver disease / cirrhosis
- Body weight variation (self-reported) >5% within 3 months before Visit 1 (screening)
- Medications for obesity (including over-the-counter medications) within 3 months before Visit 1 (screening)
- Glycated haemoglobin (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the local laboratory at screening
- History of type 1 diabetes mellitus (T1DM) or T2DM or treatment with glucose lowering agent started within 3 months before Visit 1 (screening) Further exclusion criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Survodutide arm
|
Survodutide
Andre navn:
|
|
Aktiv komparator: Semaglutid arm
|
Semaglutide
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Absolutt endring i søvnmetabolsk hastighet (SMR) (målt i et kalorimeter i et rom) fra baseline for først å besøke en deltaker nådde minst 10% vekttap
Tidsramme: ved baseline, opptil 36 uker
|
ved baseline, opptil 36 uker
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Relativ endring i SMR (målt i et helt rom kalorimeter) fra baseline for først å besøke en deltaker nådde minst 10% vekttap
Tidsramme: ved baseline, opptil 36 uker
|
ved baseline, opptil 36 uker
|
|
Absolutt endring i fettsyreoksidasjon under søvn (målt i et kalorimeter i et rom) fra baseline for først å besøke en deltaker nådde minst 10% vekttap
Tidsramme: ved baseline, opptil 36 uker
|
ved baseline, opptil 36 uker
|
|
Relativ endring i fettsyreoksidasjon under søvn (målt i et kalorimeter i et rom) fra baseline for først å besøke en deltaker nådde minst 10% vekttap
Tidsramme: ved baseline, opptil 36 uker
|
ved baseline, opptil 36 uker
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1404-0045
- U1111-1309-3679 (Registeridentifikator: WHO register - International Clinical Trials Registry Platform (ICTRP))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD-delingstidsramme
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Tilgangskriterier for IPD-deling
For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .